These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38574699)

  • 41. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
    Metaxa AM; Clarke M
    BMJ; 2024 May; 385():e078084. PubMed ID: 38692686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Registered clinical studies investigating psychedelic drugs for psychiatric disorders.
    Siegel AN; Meshkat S; Benitah K; Lipsitz O; Gill H; Lui LMW; Teopiz KM; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2021 Jul; 139():71-81. PubMed ID: 34048997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.
    Wong S; Yu AY; Fabiano N; Finkelstein O; Pasricha A; Jones BDM; Rosenblat JD; Blumberger DM; Mulsant BH; Husain MI
    J Psychoactive Drugs; 2024; 56(4):513-529. PubMed ID: 37615379
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
    Wilkes R; Roberts DM; Liknaitzky P; Brett J
    Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents.
    McIntyre RS
    Expert Opin Drug Saf; 2023; 22(10):885-889. PubMed ID: 37635320
    [No Abstract]   [Full Text] [Related]  

  • 52. Cardiovascular safety of psychedelic medicine: current status and future directions.
    Wsół A
    Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
    White CM; Weisman N; Dalo J
    Ann Pharmacother; 2023 Sep; 57(9):1062-1075. PubMed ID: 36635883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics.
    Hadar A; David J; Shalit N; Roseman L; Gross R; Sessa B; Lev-Ran S
    J Psychoactive Drugs; 2023; 55(1):1-10. PubMed ID: 35000572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways.
    Sinha JK; Trisal A; Ghosh S; Gupta S; Singh KK; Han SS; Mahapatra M; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Bhaskar R; Mishra PC; Jha SK; Jha NK; Singh AK
    Ageing Res Rev; 2024 Apr; 96():102211. PubMed ID: 38307424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained effects of single doses of classical psychedelics in humans.
    Knudsen GM
    Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Default Mode Network Modulation by Psychedelics: A Systematic Review.
    Gattuso JJ; Perkins D; Ruffell S; Lawrence AJ; Hoyer D; Jacobson LH; Timmermann C; Castle D; Rossell SL; Downey LA; Pagni BA; Galvão-Coelho NL; Nutt D; Sarris J
    Int J Neuropsychopharmacol; 2023 Mar; 26(3):155-188. PubMed ID: 36272145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Psychedelics in Treating Anxiety Disorders.
    Feulner L; Sermchaiwong T; Rodland N; Galarneau D
    Ochsner J; 2023; 23(4):315-328. PubMed ID: 38143548
    [No Abstract]   [Full Text] [Related]  

  • 60. Are psychedelics the answer to chronic pain: A review of current literature.
    Kooijman NI; Willegers T; Reuser A; Mulleners WM; Kramers C; Vissers KCP; van der Wal SEI
    Pain Pract; 2023 Apr; 23(4):447-458. PubMed ID: 36597700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.